Healthcare >> Analyst Interviews >> November 15, 2010
Continued M&a Activity In The Specialty Pharma Space – David Amsellem – Piper Jaffray & Co.
David Amsellem is a Managing Director and Senior Research Analyst at Piper Jaffray & Co., covering specialty pharmaceuticals. Prior to joining Piper Jaffray & Co. in 2008, Mr. Amsellem spent five years at Friedman Billings Ramsey, where he was a Senior Research Analyst covering small and midcap pharmaceuticals from 2006 to 2008, and a Senior Associate on the biotechnology equity research team from 2003 to 2006. Mr. Amsellem was recognized as the number one-ranked Analyst in North America for accuracy of earnings estimates in the pharmaceuticals sector in the 2008 Financial Times/StarMine Best Brokerage Analyst survey. Mr. Amsellem has more than 10 years of Wall Street experience, including work in life sciences investment and merchant banking at Prudential Vector Healthcare. Mr. Amsellem earned his B.S. from Cornell University. Profile
TWST: What do you cover in specialty pharma?
Mr. Amsellem: Specialty pharma is something of a catchall for generic drug manufacturers, brand drug manufacturers, who are focused on products for